SRT 1720 dihydrochloride is a selective and orally active activator of SIRT1 with an EC 50 of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3.
性状
Solid
IC50 & Target[1][2]
SIRT1 0.10 μM (EC50)
体外研究(In Vitro)
即使在没有 SIRT1 的情况下,SRT 1720 dihydrochloride 也能有效地降低细胞中 p53 的乙酰化,这归因于组蛋白乙酰转移酶 p300。 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
SRT 1720 (10, 30, 100 mg/kg, p.o.) dihydrochloride 处理显著降低 Lep 小鼠的空腹血糖至接近正常水平。
SRT 1720 dihydrochloride 能够保护小鼠免受饮食诱导的肥胖的负面影响,并通过 SIRT1 的下游靶点,如 PGC1α 和 FOXO1,与脂肪酸和氧化代谢的代谢适应有关。
SRT 1720 (50-100 mg/kg, p.o.) dihydrochloride 在肺气肿发展过程中减弱弹性酶诱导的气道扩大和肺功能损害,并降低野生小鼠的动脉氧饱和度。 has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Milne JC et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29;450(7170):712-6[2]. Baur JA, et al. Are sirtuins viable targets for improving healthspan and lifespan?,Nat Rev Drug Discov. 2012 Jun 1;11(6):443-61[3]. Yao H, et al. SIRT1 protects agai
溶解度数据
In Vitro: DMSO : 85 mg/mL (156.69 mM; Need ultrasonic)配制储备液